tbuckley/cabot-search huggingface dataset:
The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: A longitudinal analysis – Reply
Authors: Zhong-Liao Fang, Tim J. Harrison
Journal: Journal of Hepatology (2009)

Pan et al. [[1]Pan X.P. Huang H. Du W.B. Li L.J. The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: A longitudinal analysis.J Hepatol. 2009; 51: 411-412Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar] have expressed two concerns regarding our study. First, although no study subjects received antiviral therapy during the period of follow-up, some individuals may have been treated prior to the study. The members of the Long An cohort are low-income agricultural workers unlikely to be able to afford antiviral drugs, and none reported their use when questioned specifically at recruitment. Even if a few individuals had received therapy previously, their viral loads should have rebounded after the end of treatment and the longitudinal analysis carried out ensured that our results would not have been influenced. Furthermore, the differential effects of BCP mutations on viral load in HBeAg-positive and in HBeAg-negative patients have been reported by other investigators [[2]Chu C.J. Keeffe E.B. Han S.H. Perrillo R.P. Min A.D. Soldevila-Pico C. et al.Prevalence of HBV precore/core promoter variants in the United States.Hepatology. 2003; 38: 619-628Crossref PubMed Scopus (181) Google Scholar]. The strength of our study lies in the longitudinal analysis. Their second point is that other factors, such as age, sex and viral genotype, may have influenced the viral loads. As stated in the methods Section 2.7.1 'Cross-sectional analysis', multiple linear regression analysis was used to assess whether any differences detected remained significant after adjusting for HBeAg status and those specific factors [[3]Fang Z.L. Sabin C.A. Dong B.Q. Wei S.C. Chen Q.Y. Fang K.X. et al.The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: a longitudinal analysis.J Hepatol. 2009; 50: 273-280Abstract Full Text Full Text PDF PubMed Scopus (45) Google Scholar]. That was the case, although, for reasons of brevity, those analyses were not detailed in the paper. We do not consider that either of these issues compromises our findings.
Phase II randomized, double-blind, study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients hcrn GI14-198.
Authors: Walid Labib Shaib, Bert O'Neil, Bassel F. El-Rayes, Steven J. Cohen, Tina Ashley Khair, Erwin L. Robin, Timothy K. Huyck, Rebecca A. Redman, Ashwin Reddy Sama, Mohamad Kassar, Tanios S. Bekaii-Saab
Journal: Journal of Clinical Oncology (2019)

TPS475 Background: The prognosis of pancreas adenocarcinoma (PCA) remains poor. A chemotherapy backbone is the current standard of care in PCA. The choice of a chemotherapeutic backbone may impact the efficacy of anti-angiogenic therapy in PCA. Ramucirumab has increased activity with fluoropyrimidines (5FU) because 5FU increases VEGF expression. Methods: This is a double-blind, placebo controlled Phase II study. Subjects will receive either Ramucirumab or a placebo followed by mFOLFIRINOX every two weeks of a 28 day cycle until progression or discontinuation for other reasons. The primary endpoint of this clinical trial is nine month PFS defined as the time from enrollment to the time of progression or death. Among the key inclusion criteria, subjects must have recurrent or metastatic pancreas adenocarcinoma (PCA) with no prior first-line systemic treatment, ECOG PS 0-1, adequate organ function, no DVT, PE or other thromboembolism within three months of randomization. Total number of patient enrolled as of September 19, 2018 is 48 of 85 at eight sites; 27 male (56%), 42 Caucasians (87.5%), three African American (6.2%), one Asian (2%). Median age is 63 (40 - 76). Majority of patients (41) had de novo metastatic disease and six with recurrent disease after surgery. Regimen has been tolerated well with no unanticipated events. Clinical trial information: NCT02581215.
Emphysema produced in dogs by cigarette smoking
Authors: O. Auerbach
Journal: JAMA (1967)

Ten dogs smoked cigarettes daily in two sessions each day by voluntary inhalation through a tracheostomy tube. Five dogs died during the course of the experiment, and the remaining five were killed after more than 420 days of smoking. Hematocrit values increased markedly during the first several weeks of smoking and then declined somewhat but remained higher than presmoking levels. The heart weight relative to body weight was markedly higher in the ten smoking dogs than in the ten control dogs. Pulmonary fibrosis and emphysema, similar to those conditions in human beings, were found in all five of the smoking dogs killed. No such lung parenchymal changes were found in ten control dogs.
Author Index Vol. 68, 1999
Authors: Irena Heszen-Niejodek, Louis A. Gottschalk, Maciej Januszek, G. Majella de Jong, Eric van Sonderen, Paul M.G. Emmelkamp, Miranda A.L. van Tilburg, Elisabeth H.M. Eurelings-Bontekoe, Ad J.J.M. Vingerhoets, Guus L. van Heck, Barbara Mangweth, Georg Kemmler, Christoph Ebner, Christine De Col, Johannes Kinzl, Wilfried Biebl, Ad Vingerhoets, J. López-Castillo, M. Gurpegui, J.L. Ayuso-Mateos, J.D. Luna, J. Catalan, Carol S. Stilley, David J. Miller, Jan D. Manzetti, Ignazio R. Marino, Robert J. Keenan, Barbara Buddeberg-Fischer, Richard Klaghofer, Victoria Reed, Giovanni A. Fava, Lara Mangelli, Brunna Tuschen-Caffier, Claus Vögele, Mutsuhiro Nakao, Shinobu Nomura, Tatsuo Shimosawa, Toshiro Fujita, Tomifusa Kuboki
Journal: Psychotherapy and Psychosomatics (1999)
Mantle cell lymphoma: 2012 update on diagnosis, risk‐stratification, and clinical management
Authors: Julie M. Vose
Journal: American Journal of Hematology (2012)

Abstract Disease Overview: Mantle cell lymphoma (MCL) is a non‐Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood, and bone marrow with a short remission duration to standard therapies and a median overall survival of 4–5 years. Diagnosis: Diagnosis is based on lymph node, bone marrow, or tissue morphology of centrocytic lymphocytes, small cell type, or blastoid variant cells. A chromosomal translocation t (11:14) is the molecular hallmark of MCL, resulting in the overexpression of cyclin D1. Cyclin D1 is detected by immunohistochemistry in 98% of cases. The absence of SOX‐11 or a low Ki‐67 may correlate with a more indolent form of MCL. The differential diagnosis of MCL includes small lymphocytic lymphoma, marginal zone lymphoma, and follicular lymphoma. Risk Stratification: The mantle cell lymphoma international prognostic index (MIPI) is the prognostic model most often used and incorporates ECOG performance status, age, leukocyte count, and lactic dehydrogenase. A modification of the MIPI also adds the Ki‐67 proliferative index if available. The median overall survival (OS) for the low‐risk group was not reached (5‐year OS of 60%). The median OS for the intermediate risk group was 51 and 29 months for the high‐risk group. Risk‐Adapted Therapy: For selected indolent, low MIPI MCL patients, initial observation may be appropriate therapy. For younger patients with intermediate or high risk MIPI MCL, aggressive therapy with a cytarabine containing regimen ± autologous stem cell transplantation should be considered. For older MCL patients with intermediate or high risk MIPI, combination chemotherapy with R‐CHOP, R‐Bendamustine, or a clinical trial should be considered. At the time of relapse, agents directed at activated pathways in MCL cells such as bortezomib (NFkB inhibitor), BTK inhibitors or CAL‐101 (B‐cell receptor inhibitors) or lenalidamide (antiangiogenesis) have clinical activity in MCL patients. Autologous or allogeneic stem cell transplantation can also be considered in young patients. Am. J. Hematol. 87:604–609, 2012. © 2012 Wiley Periodicals, Inc.
Software
Authors: Orest Dubynsky
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Postpartum assessment of maternal-fetal incompatibility. Use of a programmable calculator for interpretive reporting of laboratory data
Authors: A. Lupovitch
Journal: JAMA (1976)

THE INCREASED volume and variety of clinical laboratory tests require new approaches in presenting data to the physician so that reports are clear, concise, and informative. In addition, the need for a logical series of data to answer a physician's query has induced us to assemble laboratory tests into studies geared to a specific purpose. As an example, we present a study to determine maternal candidacy for anti-Rho immune globulin serum after pregnancy to prevent Rho-sensitization, with data plus interpretation reported via a programmable calculator.<sup>1</sup>The study also checks for maternal-fetal ABO incompatibility, and, if present, for homologous antibodies in the infant's cord blood.<sup>2</sup> <h3>Programmable Calculator</h3> Two major problems arise from this approach to laboratory testing. First, since the study is based on a variable sequence of tests from which subsequent tests are selected according to the result of a preceding test, the series must be monitored for
Cover Image, Volume 40, Issue 3
Authors: Jennifer R. Baker, Jennette A. Sakoff, Adam McCluskey
Journal: Medicinal Research Reviews (2020)

Description of the front cover image: The cover image is based on the REVIEW ARTICLE The Aryl hydrocarbon Receptor (AhR) as a Breast Cancer Drug Target by Jennifer R. Baker et al., https://doi.org/10.1002/med.21645.
Genetic Risk Factors for the Development of Osteonecrosis in Children Under Age 10 Treated for Acute Lymphoblastic Leukemia
Authors: Seth E. Karol, Wenjian Yang, Leonard A. Mattano, Kelly W. Maloney, Colton Smith, Chengcheng Liu, Laura B. Ramsey, Christian A. Fernandez, Tamara Y. Chang, Geoffrey A. Neale, Cheng Cheng, Elaine R Mardis, Robert S. Fulton, Paul Scheet, Eric C. Larsen, Mignon L. Loh, Elizabeth Raetz, Stephen P Hunger, Meenakshi Devidas, Mary V. Relling
Journal: Blood (2015)
'Blood Pressure Month' brings recommendations
Authors: M. F. Goldsmith
Journal: JAMA (1984)

There's good reason to celebrate National High Blood Pressure Month right now. "The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure," appearing in the current (May) issue of the American Medical Association'sArchives of Internal Medicine, reflects several significant events since the committee's 1980 report. Because these events—publication of major clinical trial results, introduction of new antihypertensive agents, evidence concerning effectiveness of nonpharmacologic treatment, and further analysis of data relating BP levels to the risk of premature morbidity and mortality—affect the successful management of hypertension, the report contains a number of new recommendations for physicians. Recommendations on the following topics are included: Screening and referral procedures. Classification according to BP levels. Use of nonpharmacologic therapies. Revised stepped-care approach. Management of mild hypertension. Patient-professional interaction. Management of BP in special groups including blacks, children, and pregnant women. In addition, according to committee member
O prodolzhitelnosti zhizni geterogennykh i gomogennykh eritrotsitov v krovyanom rusle rettsipienta; eksperimentalnoe issledovanie
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE EMPTYING OF THE GALLBLADDER
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Review Eye, Ear, Nose and Throat for Nurses . By Jay G. Roberts, Ph.G., M.D., F.A.C.S., Chief of Staff, Eye, Ear, Nose and Throat, Los Angeles County Health Center. First Edition. Cloth, pp. 213, with 102 half-tone and line engravings. Philadelphia, F. A. Davis Company. Price $2.25.
Journal: New England Journal of Medicine (1932)
<i>Brucella</i> in Raw Milk Prompts Health Warning in Texas
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Research Quarterly, Washington
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Differential Responses of Immune Cells to Type I Interferon Contribute to Host Resistance to Viral Infection
Authors: Thomas Baranek, Thien-Phong Vu Manh, Yannick Alexandre, Muhammad Ahmad Maqbool, Joaquin Zacarias Cabeza, Elena Tomasello, Karine Crozat, Gilles Bessou, Nicolas Zucchini, Scott H. Robbins, Eric Vivier, Ulrich Kalinke, Pierre Ferrier, Marc Dalod
Journal: Cell Host & Microbe (2013)
Not . . . achalasia.
Authors: J R Bennett
Journal: BMJ (1984)

ringing the changes.We have become accustomed to describing table sugar as "empty calories," but if we include fats (largely empty calories) and alcohol then we are, on average, relying on one third of our food to supply all our nutrients.Palatable meals can be devised from foods which provide protein, fibre, and vitamins as well as energy.If patients in hospital eat poorly then the likelihood of meeting their enhanced needs is remote even with modernised catering facilities.There is more to good nutrition than a good kitchen.Clinicians need to recognise that they have a re- sponsibility for the nutritional care of their patients, and the question "what did you eat today ?" should be included in the houseman's daily round.
Fever induced by labetalol
Authors: B. H. Stricker
Journal: JAMA (1986)

Fever caused by [β-adrenoceptor blocking agents is rare. We describe fever in two patients who had been treated with labetalol. In both patients, two challenge periods were rapidly followed by a relapse, whereas on each occasion there was normalization of temperature after discontinuation of the drug therapy. This reaction is rare and unpredictable. Because there was a clear sensitization period of three to four weeks, dose independency, and an accelerated reaction to rechallenge, this adverse effect seems to be caused by an immunoallergic reaction. (<i>JAMA</i>1986;256:619-620)
Injection Errors
Authors: T. D. Whittet
Journal: BMJ (1948)

inask with wrinkled forehead, there were tremors of the hands, the yight worse than the left.She was walking with short shuffling steps, holding on to furniture indoors, and with a stick and the assistance of her daughter out of doors.Pro-, retro-, and latero- )pulsion were marked.She suffered from insomnia, and had great difficulty in turning over in bed.Her deep reflexes were increased.She was of high intelligence and spoke with a monotonous voice.I began with intramuscular injections of 15 mg. of d-tubocurarine chloride in oil (30 mg. in 1 ml.), and worked up to 45 mg.On 15 mg.she had no reaction, apart from slight weakness which lasted for a day or two.On 45 mg.she had very severe side-effects, Wasting up to seven days, when she was confined to bed, unable to get up owing to weakness, with a feeling of impending death, after
The House: Its Unique Problems in Hygiene
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FRANÇOIS MAGENDIE
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal